Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review

Clin Infect Dis. 2018 Mar 19;66(7):1122-1132. doi: 10.1093/cid/cix870.

Abstract

Cryptococcal meningitis (CM) is the primary cause of meningitis in adults with human immunodeficiency virus (HIV) infection and an emerging disease in HIV-seronegative individuals. No literature review has studied the long-term outcome of CM. We performed a systematic review on the long-term (≥3-month) impact of CM (Cryptococcus neoformans and Cryptococcus gattii) on mortality and disability in HIV-infected and non-HIV-infected adults. Although the quality of current evidence is limited, the long-term impact of CM on survival and disability seems to be high. One-year mortality ranged from 13% in an Australian non-HIV-infected C. gattii-infected cohort to 78% in a Malawian HIV-infected cohort treated with fluconazole monotherapy. One-year impairment proportions among survivors ranged from 19% in an Australian C. gattii cohort to >70% in a Taiwanese non-HIV- and HIV-infected cohorts. Ongoing early therapeutic interventions, early detection of impairments and access to rehabilitation services may significantly improve patients' survival and quality of life.

Publication types

  • Systematic Review

MeSH terms

  • Antifungal Agents / therapeutic use
  • Australien
  • Cryptococcus gattii
  • Cryptococcus neoformans / pathogenicity
  • Disabled Persons
  • Fluconazole / therapeutic use
  • HIV Infections / complications
  • HIV Infections / microbiology
  • Humans
  • Meningitis, Cryptococcal / complications*
  • Meningitis, Cryptococcal / drug therapy
  • Meningitis, Cryptococcal / mortality*
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Risk Factors

Substances

  • Antifungal Agents
  • Fluconazole